OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma highlights recent FDA feedback, cash position and upcoming Phase 3 NCP trial alongside its Cantor conference fireside chat.

Rhea-AI Summary

OKYO Pharma (OKYO) will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 8:35 AM ET, featuring Chief Medical Officer Flavio Mantelli and Chief Development Officer Gary Jacob, moderated by Cantor Fitzgerald’s Eric Fitzgerald.

The company will also be available for one-on-one meetings during the event. OKYO links this participation to recent positive FDA Type D meeting feedback that validated the regulatory and clinical path for its NCP candidate urcosimod, a strengthened cash position disclosed in its latest Annual Report, and plans to start a global Phase 3 pivotal trial in the second half of the year with about 111 patients on a single-dose regimen.

Key Terms

phase 3 pivotal clinical trial, neuropathic corneal pain

2 terms

phase 3 pivotal clinical trial medical

"initiate a global Phase 3 pivotal clinical trial"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

neuropathic corneal pain medical

"therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.

Details of the event are as follows:

Presenters: Flavio Mantelli, MD, PhD, Chief Medical Officer, Gary Jacob, PhD, Chief Development Officer

Date/Time: Thursday, September 10 at 8:35 AM ET

Moderator: Eric Fitzgerald, Cantor Fitzgerald

The Company will be available for one-on-one meetings during the conference.

The Company's presence at the events follows recent positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting, which validated OKYO's regulatory and clinical path forward for urcosimod, as well as the filing of its Annual Report reflecting a strengthened cash position.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com